Aurobindo Pharma Limited — JV/Acquisition, 29-08-2025: Acquisition

Aurobindo Pharma is internally moving its biologics asset, CuraTeQ Biologics s.r.o. Its subsidiary, Helix Healthcare B.V., will transfer its entire 100% stake in CuraTeQ to another wholly-owned subsidiary, Curateq Biologics B.V. This strategic realignment aims to consolidate Aurobindo's biologics operations. The completion of this internal share transfer, initially planned for August 31, 2025, is now expected by September 30, 2025, due to administrative delays in the Netherlands. This is an internal portfolio optimization, not a new external acquisition.